These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 25942398

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 3. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K, Hay JH, Wilson DC.
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [Abstract] [Full Text] [Related]

  • 4. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
    Dahele M, Ung YC, Ehrlich L, Silverberg J, Balogh J, Wong CS.
    J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
    [Abstract] [Full Text] [Related]

  • 5. The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
    Cochet A, David S, Moodie K, Drummond E, Dutu G, MacManus M, Chua B, Hicks RJ.
    Cancer Imaging; 2014 Apr 22; 14(1):13. PubMed ID: 25608599
    [Abstract] [Full Text] [Related]

  • 6. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun 22; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 7. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V, Odalovic S, Sobic-Saranovic D, Petrovic M, Stojiljkovic M, Petrovic N, Kozarevic N, Grozdic-Milojevic I, Obradovic V.
    Hell J Nucl Med; 2015 Jun 22; 18(1):35-41. PubMed ID: 25840571
    [Abstract] [Full Text] [Related]

  • 8. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM, DeLoia JA, Gallion H, Avril N.
    Gynecol Oncol; 2007 Apr 22; 105(1):17-22. PubMed ID: 17208284
    [Abstract] [Full Text] [Related]

  • 9. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.
    PLoS One; 2014 Apr 22; 9(12):e115127. PubMed ID: 25517451
    [Abstract] [Full Text] [Related]

  • 10. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S.
    BJU Int; 2013 Oct 22; 112(6):729-34. PubMed ID: 23790129
    [Abstract] [Full Text] [Related]

  • 11. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS, Shahin MA.
    Nucl Med Commun; 2012 Mar 22; 33(3):313-21. PubMed ID: 22237387
    [Abstract] [Full Text] [Related]

  • 12. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ, Liou WS, Liu RS, Hu C, Tsay DG, Liu CB.
    Cancer Biother Radiopharm; 2011 Apr 22; 26(2):175-81. PubMed ID: 21510748
    [Abstract] [Full Text] [Related]

  • 13. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G.
    Nucl Med Commun; 2011 Dec 22; 32(12):1162-8. PubMed ID: 21946617
    [Abstract] [Full Text] [Related]

  • 14. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?
    Israel O, Mor M, Guralnik L, Hermoni N, Gaitini D, Bar-Shalom R, Keidar Z, Epelbaum R.
    J Nucl Med; 2004 Dec 22; 45(12):2045-51. PubMed ID: 15585480
    [Abstract] [Full Text] [Related]

  • 15. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
    Lee DY, Lee CH, Seo MJ, Lee SH, Ryu JS, Lee JJ.
    Ann Nucl Med; 2014 Oct 22; 28(8):789-95. PubMed ID: 24965850
    [Abstract] [Full Text] [Related]

  • 16. Optimal timing of post-treatment [18F]fluorodeoxyglucose-PET/CT for patients with head and neck malignancy.
    Nakamura S, Toriihara A, Okochi K, Watanabe H, Shibuya H, Kurabayashi T.
    Nucl Med Commun; 2013 Feb 22; 34(2):162-7. PubMed ID: 23196675
    [Abstract] [Full Text] [Related]

  • 17. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
    Keidar Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, Ben-Nun A, Israel O.
    J Nucl Med; 2004 Oct 22; 45(10):1640-6. PubMed ID: 15471827
    [Abstract] [Full Text] [Related]

  • 18. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.
    Ann Surg; 2009 Dec 22; 250(6):957-63. PubMed ID: 19687736
    [Abstract] [Full Text] [Related]

  • 19. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
    van der Veldt AA, Buist MR, van Baal MW, Comans EF, Hoekstra OS, Molthoff CF.
    J Nucl Med; 2008 Dec 22; 49(12):1936-43. PubMed ID: 18997039
    [Abstract] [Full Text] [Related]

  • 20. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H, Henderson RW, Conti PS.
    J Comput Assist Tomogr; 2007 Dec 22; 31(2):223-8. PubMed ID: 17414758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.